Phase I, first-in-human study of BMS747158, a novel 18F-labeled tracer for myocardial perfusion PET: dosimetry, biodistribution, safety, and imaging characteristics after a single injection at rest.
about
PET probes beyond (18)F-FDGNew SPECT and PET radiopharmaceuticals for imaging cardiovascular diseaseAdvanced tracers in PET imaging of cardiovascular diseaseCoronary vascular dysfunction and prognosis in patients with chronic kidney disease.Effect of the prosthetic group on the pharmacologic properties of 18F-labeled rhodamine B, a potential myocardial perfusion agent for positron emission tomography (PET).Mitochondrial-Targeted Molecular Imaging in Cardiac DiseaseAutomatic 3D registration of dynamic stress and rest (82)Rb and flurpiridaz F 18 myocardial perfusion PET data for patient motion detection and correction.Properties of an ideal PET perfusion tracer: new PET tracer cases and data.Absolute quantitation of myocardial blood flow in human subjects with or without myocardial ischemia using dynamic flurpiridaz F 18 PETPhase II safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: flurpiridaz F 18 positron emission tomography.Myocardial defect detection using PET-CT: phantom studies.Cardiac PET perfusion tracers: current status and future directions.Development of kit formulations for (99m) TcN-MPO: a cationic radiotracer for myocardial perfusion imaging.CFR and FFR assessment with PET and CTA: strengths and limitations.Myocardial perfusion imaging with PETSynthesis and Evaluation of (18)F-labeled Pyridaben Analogues for Myocardial Perfusion Imaging in Mice, Rats and Chinese mini-swine.Radiation dosimetry of the α4β2 nicotinic receptor ligand (+)-[18F]flubatine, comparing preclinical PET/MRI and PET/CT to first-in-human PET/CT results.Assessment of radiation dose in nuclear cardiovascular imaging using realistic computational models.Pet Imaging and its Application in Cardiovascular Diseases.Advances in PET myocardial perfusion imaging: F-18 labeled tracers.Practical issues regarding the incorporation of PET into a busy SPECT practice.Non-invasive quantification of coronary vascular dysfunction for diagnosis and management of coronary artery disease.PET: Is myocardial flow quantification a clinical reality?Diagnosing coronary artery disease with hybrid PET/CT: it takes two to tango.Cardiac PET for translational imaging.Mini-Review on Cardiac Metabolic Imaging: current imaging modalities and future perspectives.Rapid computation of single PET scan rest-stress myocardial blood flow parametric images by table look up.Research Progress on 18F-Labeled Agents for Imaging of Myocardial Perfusion with Positron Emission Tomography.Single-scan rest/stress imaging: validation in a porcine model with 18F-Flurpiridaz.Synthesis and bioevaluation of 4-chloro-2-tert-butyl-5-[2-[[1-[2-[(18) F]fluroethyl]-1H-1,2,3-triazol-4-yl]methyl]phenylmethoxy]-3(2H)-pyridazinone as potential myocardial perfusion imaging agent with PET.PET imaging in heart failure: the role of new tracers.LMI1195 PET imaging in evaluation of regional cardiac sympathetic denervation and its potential role in antiarrhythmic drug treatment.Value of Hybrid Imaging with PET/CT to Guide Percutaneous Revascularization of Chronic Total Coronary OcclusionPET should replace SPECT in cardiac imaging for diagnosis and risk assessment of patients with known or suspected CAD: Pro.[18F]-BMS-747158-02PET imaging for evaluating hepatic mitochondrial complex 1dysfunction in a mouse model of non-alcoholic fatty liver disease.Radiopharmaceutical tracers for cardiac imaging.New chemical and radiochemical routes to [18F]Rho6G-DEG-F, a delocalized lipophilic cation for myocardial perfusion imaging with PET.Advances in clinical application of quantitative myocardial perfusion imagingPositron Emission Tomography in the Diagnosis and Management of Coronary Artery Disease
P2860
Q27004457-33907851-CC1A-4AA8-8CEB-9D58AC2576EAQ27011866-138655B2-9960-434C-B28B-FA33C1166FD1Q27023690-C4067F3D-3893-4854-98A7-D72473AA894DQ30448743-631681BC-3450-4897-A52B-D221653D2759Q30532190-0BEFF303-7AB8-42A5-AE0A-4383BAA48D30Q33790688-0D9659C3-42D7-40D2-A761-A45C75804D5DQ34065306-58AA6FCD-9038-421F-8BD7-E5FA57E00F44Q34132862-07F3B3CE-D6C5-4BE4-9B8B-1A13E28A2D33Q35044167-B63B2D18-5B82-4434-B844-AC323F0B843DQ35047860-A9A5FF90-EEB4-4F06-A824-4C3D98DEE468Q35088592-24FA91B9-E810-4D22-8B3C-DC289F644026Q35097258-9B0839FE-270D-4085-897B-A183DB530D17Q35230031-3BAA0362-E172-448C-A10C-70822896899DQ36081581-BFA0241E-96EF-4650-926E-A90EE9842307Q36834147-E322EAFE-DF27-42E5-840B-FDE5E080092CQ37267327-DCC1E4AD-FE89-4A02-BBBF-45C78C5407C7Q37358441-F09AB02D-8AD7-4E5E-AEC5-DDBFDF7AE99FQ37490259-D540BE48-E67E-4096-8E3E-BEA88DEF9BC5Q37743798-E663D275-212F-423A-9AF4-154B9497C5A7Q37954215-419084F0-ADA2-497C-9AC8-DE3A7F7DFCF7Q37967433-F13CB845-F259-46D4-A806-37E2C92577A6Q38020118-556D7644-99C8-4A3E-9AB1-C11CC27ECA3CQ38021718-DD2CA56B-A974-46B3-A8AE-CEB9077B16D9Q38120658-013ED572-28DD-4C25-A53A-2D868E006ADCQ38430736-AD28D090-AB48-4136-8227-143E691808B9Q38687598-A9DA70FF-9206-4E45-9642-23BC50D7BF96Q38736565-DF190629-974B-42FC-9FFF-FDE307CAC959Q38737734-DED060BD-5439-40E7-BCD0-8858E4F5C76CQ38862470-87D7DFDE-5204-49E4-B01A-C8AD4B7F7330Q38993426-8B8EEB2D-4032-4B7B-9818-69A2534FDCD4Q39285234-8BA1D52D-B57A-4652-A2BF-E888BFDAD386Q39302135-73742EBB-CDC1-49E3-8474-CCA86A4EB66AQ42535948-8E2DEAE4-48C5-427D-9932-BB001F06C948Q43658240-F7B3BDCC-6F25-4DB1-A64B-EC127DFA36A0Q47094719-8DE0744C-4E7A-48C2-933C-F37F953CC5E3Q49352380-775D3219-352C-4BC7-927A-9ED73F45033DQ49585267-85A9E437-C420-4040-A077-027623D82884Q57622205-C43A5452-31E5-4318-A995-4169C48C247DQ57824847-475C2665-97AC-4B0A-AE56-A7193F8BD867
P2860
Phase I, first-in-human study of BMS747158, a novel 18F-labeled tracer for myocardial perfusion PET: dosimetry, biodistribution, safety, and imaging characteristics after a single injection at rest.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Phase I, first-in-human study ...... er a single injection at rest.
@en
Phase I, first-in-human study ...... er a single injection at rest.
@nl
type
label
Phase I, first-in-human study ...... er a single injection at rest.
@en
Phase I, first-in-human study ...... er a single injection at rest.
@nl
prefLabel
Phase I, first-in-human study ...... er a single injection at rest.
@en
Phase I, first-in-human study ...... er a single injection at rest.
@nl
P2093
P1476
Phase I, first-in-human study ...... er a single injection at rest.
@en
P2093
Alexander Ehlgen
Heinrich Schelbert
Jamshid Maddahi
Joel Lazewatsky
Johannes Czernin
Magnus Dahlbom
Marybeth Devine
Michael Phelps
Paul Crane
P304
P356
10.2967/JNUMED.111.092528
P407
P577
2011-08-17T00:00:00Z